Therapeutic potential of CB2 targeting in multiple sclerosis

Expert Opinion on Therapeutic Targets
Fabian DocagneCarmen Guaza

Abstract

Cannabinoids have been shown to exert beneficial actions in different animal models of multiple sclerosis (MS). However, the use of cannabinoids compounds in human therapy is greatly limited by their psychoactivity. Thus, new hopes in MS therapy have arisen from the evidence for a cannabinoid receptor, termed CB2, which is devoid of psychoactive effects in animal models. This review discusses the different mechanisms by which CB2 activation could induce therapeutic actions in MS. Particular focus is given to the potential effects on inflammation/autoimmunity, remyelination and neuroprotection. This review discusses the importance of glial cells in sustaining these effects, as well as the putative secondary effects that would limit the use of CB2 agonists in the treatment of MS.

References

Aug 5, 1997·Proceedings of the National Academy of Sciences of the United States of America·C MatuteR Miledi
Jan 1, 1997·European Neurology·P ConsroeR Pertwee
Dec 10, 1999·Proceedings of the National Academy of Sciences of the United States of America·L HanusE Fride
Dec 29, 1999·Nature Medicine·T SmithL Turski
Dec 29, 1999·Nature Medicine·D PittC S Raine
Jan 29, 2000·Brain : a Journal of Neurology·G LovasS Komoly
May 24, 2001·Current Opinion in Neurology·P M Matthews, D L Arnold
Aug 22, 2001·Pain·Philip T MalanAlexandros Makriyannis
Jan 12, 2002·Current Opinion in Pharmacology·Leslie Iversen, Victoria Chapman
May 9, 2002·Journal of the Neurological Sciences·Xue MingPeter C Dowling
Dec 28, 2002·Springer Seminars in Immunopathology·Ikuo Tsunoda, Robert S Fujinami
May 7, 2003·Biochemical Pharmacology·Giorgio OrtarVincenzo Di Marzo
Jul 23, 2003·Neuroscience Research·Shin HisaharaMasayuki Miura
Jul 24, 2003·Brain : a Journal of Neurology·Gareth PryceDavid Baker
Oct 4, 2003·Science·Giovanni MarsicanoBeat Lutz
Dec 30, 2004·Neurology·Edward J Fox
Feb 12, 2005·Proceedings of the National Academy of Sciences of the United States of America·Mohab M IbrahimT Philip Malan
Mar 8, 2005·Journal of Neurochemistry·Leyre MestreCarmen Guaza
Apr 27, 2005·Neurology·George P A RicePeter A Calabresi
Aug 10, 2005·Journal of Neurochemistry·Katarzyna MareszBonnie N Dittel
Aug 23, 2005·Molecular Pharmacology·Martin R PriceRuth A Ross
Oct 29, 2005·Journal of Neurology·Massimo Filippi, Maria Assunta Rocca

❮ Previous
Next ❯

Citations

Jun 16, 2010·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Santhi GorantlaLarisa Poluektova
Feb 4, 2010·Pharmacogenetics and Genomics·Alex CarrasquerZhao-Hui Song
Jul 20, 2010·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·L KiferleP Piccini
Nov 1, 2009·Expert Review of Clinical Pharmacology·Eva de LagoJavier Fernández-Ruiz
Sep 2, 2008·Expert Review of Neurotherapeutics·Albert Lo
Dec 17, 2009·Bioorganic & Medicinal Chemistry Letters·Eric J GilbertDaniel J Lundell
Jun 17, 2016·Journal of Medicinal Chemistry·Paula MoralesNadine Jagerovic
Oct 4, 2016·Frontiers in Molecular Neuroscience·Pekka PoutiainenAnna-Liisa Brownell
Aug 30, 2008·Multiple Sclerosis : Clinical and Laboratory Research·M GironiG Martino
Feb 25, 2014·Clinical Nuclear Medicine·Flavia NiccoliniMarios Politis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.